Manuel Bloom, MD
Pulmonary Disease · Houston, TXNPI 1023029089
Payments from drug & device makers
Across 960 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$3K
- Actelion Pharmaceuticals US, Inc.$2K
- Boehringer Ingelheim$2K
- Sanofi$971
- United Therapeutics Corporation$898
- plus $8K from 33 others
What the payments were for
- Consulting fees$190%
- Food & beverage$19,80499%
- Education$2661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 194 | $3,098 |
| AstraZeneca(2 entities) | 122 | $2,815 |
| Actelion Pharmaceuticals US, Inc. | 113 | $2,498 |
| Boehringer Ingelheim | 84 | $1,961 |
| Sanofi | 31 | $971 |
| United Therapeutics Corporation | 52 | $898 |
| Regeneron Healthcare Solutions, Inc. | 28 | $843 |
| Mylan Specialty L.p. | 35 | $797 |
| Shionogi Inc | 30 | $705 |
| Mallinckrodt Hospital Products Inc. | 26 | $659 |
| Baxter Healthcare | 35 | $621 |
| Insmed, Inc. | 34 | $538 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $507 |
| Advanced Respiratory, Inc | 25 | $392 |
| Grifols USA, LLC | 11 | $380 |
| Merck | 16 | $275 |
| Bayer | 12 | $261 |
| Pfizer | 12 | $237 |
| Sunovion Pharmaceuticals Inc. | 19 | $227 |
| ANI Pharmaceuticals, Inc. | 6 | $151 |
| AbbVie | 9 | $141 |
| Jazz Pharmaceuticals Inc. | 2 | $140 |
| Genentech USA, Inc. | 2 | $132 |
| Electromed, Inc. | 6 | $82 |
| Mallinckrodt Enterprises LLC | 4 | $80 |
| Teva Pharmaceuticals USA, Inc. | 5 | $77 |
| Inogen, Inc. | 3 | $73 |
| Shire North American Group Inc | 4 | $73 |
| Resmed Corp | 2 | $62 |
| Gilead | 3 | $59 |
| Pharming Healthcare, Inc. | 3 | $51 |
| Genentech, Inc. | 1 | $48 |
| Circassia Inc. | 3 | $47 |
| Paratek Pharmaceuticals, Inc. | 2 | $45 |
| Amgen | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Johnson & Johnson | 1 | $27 |
| Viatris Specialty LLC | 1 | $26 |
| Itamar Medical Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,089 in reported general payments places this provider in the 80th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 18 | $273,333 |
| OfevNintedanib Esylate | 19 | $268,470 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 239 | $175,503 |
| Dupixent SyringeDupilumab | 12 | $41,961 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $35,492 |
| EliquisApixaban | 49 | $28,786 |
| FarxigaDapagliflozin Propanediol | 35 | $26,837 |
| OzempicSemaglutide | 29 | $24,573 |
| Spiriva RespimatTiotropium Bromide | 37 | $23,569 |
| Ambrisentan | 12 | $14,956 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $9,503 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $9,035 |
| Zafirlukast | 52 | $5,424 |
| DuleraMometasone/Formoterol | 11 | $3,782 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 92 | $3,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $1,961 | $292,03956 claims |
| Insmed, Inc.Arikayce | $538 | $273,33318 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $3,098 | $220,030319 claims |
| AstraZenecaFarxiga, Symbicort | $2,815 | $36,34153 claims |
| PfizerEliquis | $237 | $28,78649 claims |
| MerckDulera | $275 | $3,78211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Ivan RosasHouston$13.8M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Zeenat SafdarHouston$1.7M
- Howard HuangHouston$1.3M
- Dileep PuppalaHouston$1.1M
- Sandeep GuptaHouston$1.1M
- Joseph VaronHouston$1.1M
- Bela PatelHouston$974K
- Roberto CasalHouston$865K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.